Phoenix and MD Anderson expand cell therapy safety switches

Cross-licensing agreement brings reformulated rimiducid to cell and gene therapies, with implications for oncology and longevity medicine. The University of Texas MD Anderson Cancer Center and Phoenix SENOLYTIX have announced a global cross-licensing agreement around CaspaCIDe, the preeminent cell therapy “safety switch” technology validated in multiple human CAR T cell therapies. The deal provides Phoenix’s […] The post Phoenix and MD Anderson expand cell therapy safety switches appeared first on Longevity.Technology.